A health economist walks into a tech company…

…and learns good practices for reproducible analyses in health economics and outcomes research from software engineers. THE KEYS are functional programming, version control, style guides, and peer code review systems. READ ABOUT IT in the latest Value & Outcomes Spotlight magazine here. LEARN HANDS ON at our short-course Sat, May 18, 8am-Noon at the ISPOR … Continue reading A health economist walks into a tech company…

How to replicate visualization of trajectory towards UNAIDS 90-90-90 goals

In this tutorial, you’ll gain access to the R code, dataset, and motivation to replicate data visualizations in my latest paper and apply the concepts to your next one. I sat on an airplane last year, flipping through The Economist, when I froze at the sight of a tiny chart littered with a mess of … Continue reading How to replicate visualization of trajectory towards UNAIDS 90-90-90 goals

I submitted to a “look-alike” journal on purpose. This is why.

The following emails are real correspondence between myself and an Associate Editor at a prestigious scientific journal, which I have called “Journal X” here. It began after I published an article in a journal with a very similar title, a “look-alike” which I am calling “Journal Y”. Names are removed for privacy. Surprise email from … Continue reading I submitted to a “look-alike” journal on purpose. This is why.

Incentivizing health-promoting behaviors

A new comprehensive landscape analysis of Medicaid health behavior incentive programs gathers together many challenges and potential solutions in the latest issue of Health Affairs. In 2017-2018 the team interviewed 80 key-informant stakeholders and searched the literature. The most common incentive type offered by programs was gift cards or vouchers, including cash, Visa gift cards, specific venue … Continue reading Incentivizing health-promoting behaviors

data|evidence|policy|practice

The Irish Department of Health (DoH) is in the process of developing a national biosimilar medicines policy which aims to increase biosimilar use by creating a robust framework where biologicals and biosimilars can be used safely, cost-effectively, and confidently in the health service. In this example from an Irish teaching hospital, the introduction of the biosimilar first to new patients, along with a switching study executed in parallel, helped to raise prescriber confidence. Continue reading data|evidence|policy|practice